不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>行业动态>基石药业pralsetinib完成经含铂化疗的RET融合NSCLC中国患者入组

基石药业pralsetinib完成经含铂化疗的RET融合NSCLC中国患者入组

美通社2019年12月27日 3:22 点击:198

基石药业(苏州)有限公司宣布,由公司合作伙伴Blueprint Medicines开发的在研产品pralsetinib的I/II期注册性试验已完成中国最后一例经含铂化疗的RET融合非小细胞肺癌(NSCLC)患者入组。

不用本金就能赚钱的方法SUZHOU2019NIAN12YUE26RI /MEITONGSHE/ -- JISHIYAOYE(SUZHOU)YOUXIANGONGSI(YIXIAJIANCHENG“JISHIYAOYE”HUO“GONGSI”,XIANGGANGLIANJIAOSUODAIMA:2616)XUANBU,YOUGONGSIHEZUOHUOBANBlueprint MedicinesKAIFADEZAIYANCHANPINpralsetinibDEI/IIQIZHUCEXINGSHIYANYIWANCHENGZHONGGUOZUIHOUYILIJINGHANBOHUALIAODERETRONGHEFEIXIAOXIBAOFEIAI(NSCLC)HUANZHERUZU,GAISHIYANSHIZHENGZAIJINXINGDEQUANQIUI/IIQIARROWYANJIUDEYIBUFEN。ZHEIJIANGZHICHIJISHIYAOYEJIHUAZAI2020NIANXIABANNIANXIANGGUOJIAYAOPINJIANDUGUANLIJU(NMPA)DIJIAOpralsetinibZHILIAOGAISHIYINGZHENGDEXINYAOSHANGSHISHENQING。

ARROWYANJIUZHIZAIPINGGUpralsetinibZAIRETBIANYIDEWANQINSCLC、JIAZHUANGXIANSUIYANGAIHUOQITAWANQISHITILIUHUANZHEZHONGDEZONGTIHUANJIELV、HUANJIECHIXUSHIJIAN、YAODAIDONGLIXUE、YAOXIAOXUEHEANQUANXING。ZHONGGUOYANJIUZHONGXINYU2019NIAN8YUE26RISHIXIANSHOULIJINGHANBOHUALIAODERETRONGHENSCLCHUANZHEJIYAO。

肺癌是全球发病率最高的恶性肿瘤。在中国,每年约有73万确诊新发肺癌患者和61万死亡肺癌患者[1]不用本金就能赚钱的方法。在所有肺癌中,约80-85%为非小细胞肺癌,而RET融合在非小细胞肺癌中的发生率约为1~2%。目前对于RET融合非小细胞肺癌的一线标准治疗为含铂双药化疗,二线治疗为细胞毒药物或免疫检查点抑制剂的单药治疗,但疗效均不理想,且患者将遭受巨大的心理及生理痛苦,生活质量严重下降。

PralsetinibSHIYIZHONGKOUFU、QIANGXIAOQIEDUIRETRONGHEHETUBIAN(HANNAIYAOTUBIAN)JUYOUGAOXUANZEXINGDERETYIZHIJI。2018NIAN6YUE,JISHIYAOYEZIBlueprint MedicinesHUODELEBAOKUOpralsetinibZAINEIDESANZHONGYAOWUZAIZHONGGUODALU、XIANGGANG、AOMENHETAIWANDEDUJIAKAIFAHESHANGYEHUASHOUQUAN,Blueprint MedicinesBAOLIUZHEISANKUANYAOWUZAISHIJIEQITADIQUDEXIANGGUANQUANLI。

2019NIAN6YUE,Blueprint MedicinesZAIASCOFABULEARROWYANJIUZAIXIEDAIRETTUBIANAIZHENGHUANZHEZHONGDEZUIXINSHUJU。JIEGUOBIAOMING,PralsetinibXIANSHILECHIXUDEKANGZHONGLIUHUOXING,QIENAISHOUXINGLIANGHAO。NARULIAOXIAOPINGGUDEHUANZHEJUNYU2018NIAN11YUE14RIQIANRUZU,SUIFANGSHUJUJIEZHIZHI2019NIAN4YUE28RI,QIJIANHUANZHENENGGOUJIESHOUZHISHAOLIANGCIYINGXIANGXUEJIANCHA。ZHISHUJUJIEZHIRIDEJIEGUOXIANSHI:

  • 在接受每天一次pralsetinib 400mg剂量的35名可进行疗效评估的经含铂化疗的非小细胞肺癌患者中,pralsetinib的客观缓解率为60%(1例完全缓解和20例部分缓解;所有缓解均得到确认),疾病控制率达到了100%[2]

  • BULUNHUANZHESHIFOUCUNZAINAOZHUANYI,pralsetinibJUNXIANSHICHULINCHUANGHUOXING。ZAI9LICUNZAIKEPINGGUDENAOBUZHUANYIZAODEHUANZHEZHONG,7LI(78%)HUANZHENAOBUZHUANYIBINGZAOSUOXIAO。QISHIJILIANGWEI400 mgMEITIANYICIDEHUANZHEMEIYOUYINWEINAOBUXINFABINGZAOERDAOZHIJIBINGJINZHAN。

  • 不用本金就能赚钱的方法ZAIJIESHOUpralsetinib400 mgMEITIANYICIQISHIJILIANGDE226LIXIEDAIRETTUBIANDEZHONGLIUHUANZHEZHONGJUN,pralsetinibXIANSHICHULIANGHAODENAISHOUXING,YANJIUZHEBAOGAODEDADUOSHUBULIANGSHIJIAN(AEs)WEI1JIHUO2JI。

YISHANGSHUJUJUNZHICHIBlueprint MedicinesJIHUAZAI2020NIANDIYIJIDUXIANGFDADIJIAOXINSHIYINGZHENGSHANGSHISHENQING,YONGYUXIEDAIRETRONGHEDEJINGHANBOHUALIAODEFEIXIAOXIBAOFEIAIZHILIAO。

JISHIYAOYEDONGSHIZHANGJIANSHOUXIZHIXINGGUANJIANGNINGJUNBOSHIBIAOSHI:“PralsetinibMUQIANYIBEIFDASHOUYU‘TUPOXINGLIAOFARENDING’,YONGYULIANGZHONGXIEDAIRETTUBIANDEAIZHENGZHILIAO,QIEQUANQIUSHANGWUXUANZEXINGRETYIZHIJIYAOWUHUOPI。GANXIEYANJIUZHE、HEZUOHUOBANHEGONGSIGEWEITONGSHIDETONGLIHEZUO,CUSHIARROWYANJIUZAIZHONGGUOTIQIANWANCHENGLEERXIANJIYISHANGFEIXIAOXIBAOFEIAIHUANZHEDERUZU。QIDAIpralsetinibNENGGOUZAORIJINRUZHONGGUOSHICHANG,YIMIBUGUONEIHUANZHEDEXIANCUNZHILIAOKONGBAI。”

基石药业首席医学官杨建新博士表示:“发生RET融合的NSCLC患者很难从现有的治疗手段中获益。ARROW全球试验已公布的数据显示,pralsetinib在治疗具有RET突变的NSCLC中表现出令人鼓舞的抗肿瘤活性及持久的疗效,同时安全性和耐受性良好。即使是在标准治疗预后很差的脑转移患者中,仍表现出很好的疗效。值得一提的是,在NSCLC中RET融合率仅为1~2%的情况下,我们完成经含铂化疗的该类患者入组的时间仍比原定计划缩短了将近一半,这让我们切实体会到中国肺癌患者群体迫切的未被满足的临床治疗需求。我们还将继续全力推进pralsetinib在中国初治NSCLC及其他RET突变肿瘤患者的试验进展。

[1].Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66(2): 115-32.
[2].Matthew H. Taylor不用本金就能赚钱的方法, et al. Activity and tolerability of pralsetinib, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers. 2019 ASCO Abstract 6018.

关于Pralsetinib

pralsetinibSHIYIZHONGKOUFU(MEIRIYICI)、GAOXIAOHEGAOXUANZEXINGDEBAXIANGZHIAIXINGRETBIANYIDEZAIYANYAOWU。Blueprint MedicinesZHENGZAIJINXINGpralsetinibDELINCHUANGKAIFA,YONGYUZHILIAORETBIANYIDEFEIXIAOXIBAOFEIAI、JIAZHUANGXIANSUIYANGAIHEQITASHITILIUHUANZHE。MEIGUOFDAYIJINGSHOUYUpralsetinibTUPOXINGLIAOFARENDING,YONGYUZHILIAOJINGHANBOHUALIAOJINZHANDERETRONGHEFEIXIAOXIBAOFEIAI、HEXUYAOXITONGZHILIAOQIEMEIYOUKETIDAIZHILIAOFANGANDERETTUBIANJIAZHUANGXIANSUIYANGAIHUANZHEDEZHILIAO。

不用本金就能赚钱的方法pralsetinibSHIYOUBlueprint MedicinesDEYANJIUTUANDUIYIJUQIZHUANYOUHUAHEWUWENKUSUOSHEJIDE。ZAILINCHUANGQIANYANJIUZHONG,pralsetinibZHENDUIZUICHANGJIANRETJIYINRONGHE、JIHUOTUBIANHENAIYAOTUBIANSHIZHONGBIAOXIANCHUCINAMOERSHUIPINGDEXIAOJIA。QIZHONG,XIANGBIVEGFR2,pralsetinibDUIRETDEXUANZEXINGYOU90BEITIGAO。CIWAI,pralsetinibDUIRETDEXUANZEXINGYUYIPIZHUNDEDUOJIMEIYIZHIJIXIANGBIYOUXIANZHUTIGAO。TONGGUOYIZHIYUANFAHEJIFATUBIAN,pralsetinibYOUWANGKEFUHEYUFANGLINCHUANGNAIYAOXINGDEFASHENG。ZHEIZHONGZHILIAOFANGFAYUQIKEYIZAIXIEDAIBUTONGRETBIANYIDEHUANZHEZHONGSHIXIANCHIJIUDELINCHUANGHUANJIE,QIEJUYOULIANGHAODEANQUANXING。

关于基石药业

JISHIYAOYE(HKEX: 2616)SHIYIJIASHENGWUZHIYAOGONGSI,ZHUANZHUYUKAIFAJISHANGYEHUACHUANGXINZHONGLIUMIANYIZHILIAOJIJINGZHUNZHILIAOYAOWU,YIMANZUZHONGGUOHEQUANQIUAIZHENGHUANZHEDEYINQIEYILIAOXUQIU。CHENGLIYU2015NIANDI,JISHIYAOYEYIJIJIELEYIZHIZAIXINYAOYANFA、LINCHUANGYANJIUYIJISHANGYEHUAFANGMIANYONGYOUFENGFUJINGYANDESHIJIEJIGUANLITUANDUI。GONGSIYIZHONGLIUMIANYIZHILIAOLIANHELIAOFAWEIHEXIN,JIANLILEYITIAO15ZHONGZHONGLIUHOUXUANYAOWUZUCHENGDEFENGFUCHANPINGUANXIAN。MUQIAN5KUANHOUQIHOUXUANYAOWUZHENGCHUYUGUANJIANXINGLINCHUANGSHIYAN。PINGJIEJINGYANFENGFUDEGUANLITUANDUI、FENGFUDEGUANXIAN、ZHUANZHUYULINCHUANGKAIFADEYEWUMOSHIHECHONGYUZIJIN,JISHIYAOYEDEYUANJINGSHITONGGUOWEIQUANQIUAIZHENGHUANZHEDAILAICHUANGXINZHONGLIULIAOFA,CHENGWEIQUANQIUZHIMINGDEZHONGGUOLINGXIANSHENGWUZHIYAOGONGSI。

YULEJIEGENGDUO,QINGLIULAN

前瞻性申明

BENWENSUOZUOCHUDEQIANZHANXINGCHENSHUJINYUBENWENZUOCHUGAICHENSHUDANGRIDESHIJIANHUOZILIAOYOUGUAN。CHUFALVGUIDINGWAI,YUZUOCHUQIANZHANXINGCHENSHUDANGRIZHIHOU,WULUNSHIFOUCHUXIANXINZILIAO、WEILAISHIJIANHUOQITAQINGKUANG,WOMENBINGWUZERENGENGXINHUOGONGKAIXIUGAIRENHEQIANZHANXINGCHENSHUJIYULIAOZHIWAIDESHIJIAN。QINGXIYUEBENWEN,BINGLIJIEWOMENDESHIJIWEILAIYEJIHUOBIAOXIANKENENGYUYUQIYOUZHONGDACHAYI。BENWENNEISUOYOUCHENSHUNAIBENWENZHANGKANFARIQIZUOCHU,KENENGYINWEILAIFAZHANERCHUXIANBIANDONG。

消息来源:基石药业


(来源: 美通社


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图